124
Participants
Start Date
February 29, 2016
Primary Completion Date
February 28, 2017
Study Completion Date
March 31, 2017
Baricitinib
Administered orally
Placebo
Administered orally
Triamcinolone (Optional)
Administered topically
Icahn School of Medicine, New York
Medical Dermatology Specialists, Atlanta
Forward Clinical Trials, Inc, Tampa
Northwestern University, Chicago
Menter Dermatology Research Institute, Dallas
Center for Clinical Studies, Houston
Center for Clinical Studies, Houston
Center for Clinical Studies, Webster
Dermatology Research Associates, Los Angeles
Oregon Health and Science University, Portland
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Takaoka-shi
Eli Lilly and Company
INDUSTRY